Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.62%. A quarter ago, it was expected that this company would post a loss of $0.71 per share when it actually produced a loss of $0.52, delivering a surprise of +26.76%.Over the last four quarters, the company ...